Пульс - медицинский центр 
Пульс - медицинский центр
Круглосуточно
бесплатно по России
+7 (965) 177 17 74
бесплатно по России
Сульфасалазин и 5-аминосалицилат Препараты 5-АСК обладают очень слабой иммуносупрессивной активностью. Нет сообщений о том, что эти препараты связаны с повышенным риском инфицирования, а исследования, оценивающие профиль безопасности 5-АСК, не демонстрируют повышенного риска серьезных или оппортунистических инфекций. Лечение 5-АСК следует продолжать, не беспокоясь о повышенном риске заражения или развития тяжелой формы COVID-19 . Если пациент находится в контакте с больным COVID-19 или у него развивается COVID-19, лечение 5-АСК следует продолжить.
Experts refer to the third category of skin manifestations as pink lichen and papulosquamous rashes, which are infectious-allergic skin lesions associated with COVID-19 infection. The clinical feature of pink lichen in this case is the absence of maternal plaque. The fourth category includes a measles rash. To the fifth - toxicodermia. This rash is associated with individual intolerance of patients of certain groups of drugs. The sixth category of skin manifestations of coronavirus infection, scientists include urticaria, which in some cases may be a harbinger of the onset of COVID-19.
Analyzing the subjective assessment of health by student youth (under the age of 25), we found the following: the vast majority of respondents, regardless of gender, rated their own health as "good" and "very good". Almost half of the guys and every fifth girl noted the criterion for assessing "excellent" health. About 2% of boys and 3% of girls noted that they have “excellent” health. The criteria for assessing the health of "mediocre" and "poor" for the children practically did not differ. Thus, “mediocre” health was observed in 15% of boys and 14% of girls; "bad" - 2% of boys and 2% of girls.
The current COVID-19 pandemic caused by SARS-CoV-2 has become a global health emergency. Treatment of chronic inflammatory bowel disease (CIBD) according to the standards includes the use of 5-aminosalicylic acid (5-ASA), corticosteroids, cytostatics, and biological therapy. However, these treatments can weaken the immune system, which potentially puts COPD patients at increased risk of infections and infectious diseases, including COVID-19. Therefore, patients with CVD have a greater risk of developing COVID-19 and more severe clinical course, or even death, compared to the general population.
Закажите обратный звонок
Задать вопрос
Быстрая запись на прием